Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
There were a few factors that contributed to me stopping
Reduces skin irritation and inflammation
doi: 10.1182/blood-2015-11-680843 84 LiuZMiMLiXZhengXWuGZhangL
Sheehan, D., Meade, G., Foley, V
